NextCell Pharma AB’s Post

Top 20 Radiopharma Companies based on Market Cap Unveiling one of the PharmaShots' most-anticipated reports on the Top 20 Radiopharma Companies based on Market Cap This year, POINT Biopharma with a market cap of $726.88B ranks first on the list, followed by Novartis & RayzeBio with a market cap of $235.92B and $102.14B respectively For a curated report, reach out to us at connect@pharmashots.com Sign up for an early access to PDF versions of our reports: https://lnkd.in/gyTYU9ix Happy Reading! Stay Tuned! #diagnostics #theranostics #therapy #radiopharmaceuticals #marketsize #Pointbiopharma #novartis #rayzebio #pharmashots #report #top20

Partnerships can bring innovation to our space, and meaningful difference to those who need it. Ora have partnered with Kiora Pharmaceuticals, Inc. Inc. and the Choroideremia Research Foundation - Cure CHM to validate functional vision assessments for patients with profound blindness. These measurements, which are intended to correlate to improvements in everyday life, are essential to standardizing clinical trial design across the industry in order to bring about new therapies for vision impairment. Work will begin shortly. We recently received approval to initiate the related clinical work to validate the endpoints with the goal of incorporating the endpoints into our planned Phase 2 clinical trial assessing KIO-301 in an inherited retinal disease. We invite you to read more...https://hubs.la/Q02trn1g0

CD-19 Market to Witness Significant Growth During the Study Period (2019-32), Assesses DelveInsight | Horizon Therapeutics, MorphoSys, Incyte, Novartis, Bristol-Myers Squibb, Legend Biotech, Janssen #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Partnerships can make a difference. Kiora Pharmaceuticals, Inc. the Choroideremia Research Foundation - Cure CHM and Ora, Inc., have come together to validate functional vision assessments for patients with profound blindness. These measurements, which are intended to correlate to improvements in everyday life, are essential to standardizing clinical trial design across the industry in order to bring about new therapies for vision impairment. Work will begin shortly. We recently received approval to initiate the related clinical work to validate the endpoints with the goal of incorporating the endpoints into our planned Phase 2 clinical trial assessing KIO-301 in an inherited retinal disease. We invite you to read more...https://lnkd.in/eNpYGKNe

CD-19 Market to Witness Significant Growth During the Study Period (2019-32), Assesses DelveInsight | Horizon Therapeutics, MorphoSys, Incyte, Novartis, Bristol-Myers Squibb, Legend Biotech, Janssen #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Brainstorm Cell Therapeutics announced the conclusion of a significant meeting with the #FDA regarding NurOwn, a new innovative treatment for #ALS. This critical meeting aimed at securing a protocol for a Phase 3b trial. It marks a key milestone in the development of the MSC-NTF cell-based #NurOwn, offering a new, personalized approach to #ALStreatment. Chaim Lebovits, President and CEO of #BrainStorm, emphasized the significance of the meeting outcomes, stating: “Our meeting with the FDA provided us with valuable input on the Phase 3b trial design, outlining clear steps forward. We believe that an SPA will serve to help de-risk certain regulatory aspects of the NurOwn clinical program. We recognize the urgency in providing ALS patients with safe and efficacious treatments and are committed to agreeing on a regulatory path forward for NurOwn.” By Tracy Mokwe https://lnkd.in/dez9DKSs

Vertex Pharmaceuticals continues to make very strategic acquisitions. Their latest purchase is a $4.9 billion bid for Alpine Immune Sciences, Inc. - ALL CASH! M&A in biotech is just starting. Right now, we are seeing a lot of smaller, strategic deals. Soon enough, starting in late-2024, I think we will start seeing larger deals. Some of the more interesting companies to watch include: Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Beam Therapeutics, Eli Lilly and Company, Moderna, Merck, Intellia Therapeutics, Inc., CRISPR Therapeutics, Denali Therapeutics, BioMarin Pharmaceutical Inc., Editas Medicine, Illumina, Sarepta Therapeutics, Jazz Pharmaceuticals, Axsome Therapeutics, Inc., Disclosure: I own securities in $ALNY, $VRTX, $CRSP, $NTLA, $DNLI, $EDIT, and $BEAM This is not a recommendation to buy or sell any security #biotech #stocks #investment #manda #acquisition #deals #pharma #mergers

【NEWS UPDATE】🧠Gilead's $4.9 billion investment in the CD47-targeted therapy space has faced a major setback with the disappointing results of its Phase 3 clinical trial for Magrolimab in the treatment of high-risk myelodysplastic syndrome (HR-MDS). Despite initial optimism based on the Phase 1b study, the Phase 3 data showed no efficacy advantages and raised safety concerns, with a significantly higher rate of serious adverse events. 💊 This event serves as a reminder of the challenges in innovative drug development, where overly optimistic estimates can lead to heavy losses. Gilead will need to closely re-evaluate its acquisition and R&D strategies going forward, as it grapples with this substantial setback in the oncology drug landscape. 🤔 #PharmaceuticalInnovation #ClinicalTrials #RiskManagement https://lnkd.in/gDBcnDkg

https://lnkd.in/de4X-rDq Key Insights: • According to the agreement, Merck & Co., Inc., located in Rahway, New Jersey, USA, will make initial payments to Daiichi Sankyo as follows: $1.5 billion for ifinatamab deruxtecan upon signing the agreement; $1.5 billion for patritumab deruxtecan, with $750 million due upon execution and the remaining $750 million payable after 12 months; and $1.5 billion for raludotatug deruxtecan, with $750 million due upon execution and the remaining $750 million payable after 24 months Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #Health #HealthInnovation #DaiichiSankyo #collaboration #partership #HealthcareAnalytics #NewsUpdate #news #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights #Agreement

CD-19 Market to Witness Significant Growth During the Study Period (2019-32), Assesses DelveInsight | Horizon Therapeutics, MorphoSys, Incyte, Novartis, Bristol-Myers Squibb, Legend Biotech, Janssen #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech